Moderate to Severe Pain: Novel Abuse Deterrent Formulation Technologies and Emergence of Novel Mechanism in the Management of Pain

Description: Globally, pain is one of the important therapy areas with a market size of over $50b in 2013, and is expected to grow at 10%. The recent patent expiry of Cymbalta and Lyrica (2018) will have significant impact on the overall pain market size in the near future.

However, several pipeline molecules are emerging to fill this gap. The importance of abuse deterrent labeling in the formulations can be better understood from FDA's non-approval of oxycontin generics in 2013. The revised labeling with abuse deterrence has protected Purdue's oxycontin revenue slide from its generization.

In this report, we have discussed a number of novel delivery technologies employed in the formulation of abuse deterrent product, technologies employed in enhancing patient compliances and emerging novel mechanisms in the management of pain. Renewed interest on pain therapy is vision as recently Biogen Idec acquired Convergence's CNV1014802 (Nav 1.7 sodium channel blocker) to expand its neuropathic pain portfolio and we believe several such acquisitions will happen in the near term.

In this report, we have discussed a number of novel delivery technologies employed in the formulation of abuse deterrent product, technologies employed in enhancing patient compliances and emerging novel mechanisms in the management of pain. Renewed interest on pain therapy is vision as recently Biogen Idec acquired Convergence's CNV1014802 (Nav 1.7 sodium channel blocker) to expand its neuropathic pain portfolio and we believe several such acquisitions will happen in the near term.

Contents:

1. Management of Pain
   - Introduction
   - Classification of Pain (Type and Intensity)
   - Treatment of chronic pain – current approach
   - Market Size of pain and current therapeutic options (acute, chronic pain and neuropathic pain)
   - Unmet medical need and market opportunities
   - Overview of Marketed drugs for moderate to severe pain and neuropathic pain
   - Advantages and Limitations of non-opioid drugs and overview of marketed drugs
   - Necessity for non-opiate treatment – Drug abuse and tolerance
2. FDA Schedule for controlled substances and advantage of Schedule III over II
3. FDA Guidelines for the development of abuse deterrent formulations
   a. AVERSION
   b. IMPEDE
   c. DETERx
   d. PODRAS
   e. IntelliPaste
   f. nPODDDS
   g. INTAC
   h. ORADUR
   i. Implantable pump for intrathecal delivery
   j. OPTIGEL Lock
   k. Small molecule delivery
   l. Bio-MD-prodrugs platform
   m. Ligand activated Therapy (LAT)
   n. NOBUSE
   o. ORADUR
   p. EGALET
   q. Inspirion delivery Technologies
   r. Intellitab Technology
   s. Trigger lock platform – Micropump
   t. Fenrock
u. Smart Patch PNS system
5. Pipeline analysis of Novel Technologies and new mechanisms in Pain management
a. Multi-day formulation of Tramadol
b. Bio-MD Platform
c. Angiotension II antagonist
d. Anti-NGF
e. Ligand Activate Therapy
f. Nav1.7 inhibitor
g. GPCR-Dimer Screen Technology
h. CB agonist
i. Peptide Therapeutics (conopeptide)
j. TRPV1 antagonist
k. Fentanyl based therapy formulation modification (micro and nano tab)
l. Oromucosal delivery
m. Opioid alternatives (dexmedetomidine)
n. Steroidal intraarticular injection
o. TrkA receptor antagonist

6. Late stage pipeline developments in neuropathic pain
a. Cebranopadol
b. Mirogabalin
c. CNV-2197944
d. Sativex
e. Once daily pregabalin
f. Topical clonidine gel
g. Topical ketamine and amitraline
h. Eladur
i. GRC-17536
j. DWP05195

7. FDA Perspective on Abuse deterrent formulations (Opioids)
Companies mentioned:
- AbbVie
- AcelRx
- Acorda Therapeutics
- Actavis
- Acura Pharma
- Altus formulations
- Amorsa Therapeutics
- AstraZeneca
- BioDelivery Sciences International Inc
- Cara Therapeutics
- Catalent
- Charleston
- Collegium Pharma
- Convergence
- Daiichi
- Daewoong
- Depomed
- Durect
- Egalet
- Eli Lilly
- Elite Pharma
- Endo
- Flamel Technologies
- Flexion Therapeutics
- Glenmark
- Grunenthal
- Immune Pharmaceuticals
- Impax Pharmaceuticals
- Inspirion Delivery technologies
- Intelli Pharmaceuticals
- Johnson and Johnson
- KemPharm
- Kineta
- Kunwha Pharmaceutical
- Medallion Therapeutics
- Nektar
- Orbis Biosciences
- Orexo
- Pain Therapeutics
- Pfizer
- Purdue
- Relmada Therapeutics
- Signature Therapeutics
- Spinifex pharma
- SPR Therapeutics
- Teikoku
- Teva
- Trevena Inc
- Tris Pharma
- Valeant
- Xenon Pharma
- XenoPort

Tables:
- Table-1: US Pain Market Size
- Table-2: Classification Based on Intensity of Pain
- Table-3: Marketed Fentanyl Dosage Forms (US): Transdermal Patches, Buccal And Sublingual Tablets And Films For Pain Relief
- Table-4: Commonly Used Opioids For Pain Management
- Table-5: Marketed Drugs for Neuropathic Pain
- Table-6: Drug Enforcement Authority (DEA) Controlled Substances Schedule Criteria
- Table-7: Summary of Controlled Substances Act requirements
- Table-8: Common Non-Opioids – Acetaminophen and NSAIDs
- Table-9: Benefits of Sublingual Microtablets vs. IV morphine Patient Controlled Analgesia

Charts:
- Chart-1: Classification of Pain
- Chart-2: Pain Relief Ladder -WHO
- Chart-3: Neuropathic Pain market size and projection through 2020
- Chart-4: Global Healthcare Market Expenditure through 2018: Therapy Class
- Chart-5: Global NME (2008-12) Availability in 2013
- Chart-6: Death Rates 1. Management of Pain
- Introduction
- Classification of Pain (Type and Intensity)
- Treatment of chronic pain – current approach
- Market Size of pain and current therapeutic options (acute, chronic pain and neuropathic pain)
- Unmet medical need and market opportunities
- Overview of Marketed drugs for moderate to severe pain and neuropathic pain
- Advantages and Limitations of non-opioid drugs and overview of marketed drugs
- Necessity for non-opiate treatment –Drug abuse and tolerance
2. FDA Schedule for controlled substances and advantage of Schedule III over II
3. FDA Guidelines for the development of abuse deterrent formulations
4. Abuse deterrent Technology Platforms employed in marketed drugs and pipeline
a. AVERSION
b. IMPEDE
c. DETERx
d. PODRAS
e. IntelliPaste
f. nPODDDS
g. INTAC
h. ORADUR
i. Implantable pump for intrathecal delivery
j. OPTIGEL Lock
k. Small molecule delivery
1. Bio-MD-prodrugs platform
2. Ligand activated Therapy (LAT)
3. NOBUSE
4. ORADUR
5. EGALET
6. Inspirion delivery Technologies
7. Intellitab Technology
8. Trigger lock platform –Micropump
9. Fenrock
10. Smart Patch PNS system

5. Pipeline analysis of Novel Technologies and new mechanisms in Pain management
   a. Multi-day formulation of Tramadol
   b. Bio-MD Platform
   c. Angiotension II antagonist
   d. Anti-NGF
   e. Ligand Activate Therapy
   f. Nav1. 7 inhibitor
   g. GPCR –Dimer Screen Technology
   h. CB agonist
   i. Peptide Therapeutics (conopeptide)
   j. TRPV1 antagonist
   k. Fentanyl based therapy formulation modification (micro and nano tab)
   l. Oromucosal delivery
   m. Opioid alternatives (dexmedetomidine)
   n. Steroidal intraarticular injection
   o. TrkA receptor antagonist

6. Late stage pipeline developments in neuropathic pain
   a. Cebranopadol
   b. Mirogabalin
   c. CNV-2197944
   d. Sativex
   e. Once daily pregabalin
   f. Topical clonidine gel
   g. Topical ketamine and amitraline
   h. Eladur
   i. GRC-17536
   j. DWP05195

7. FDA Perspective on Abuse deterrent formulations (Opioids)

Companies mentioned:
- AbbVie
- AcelRx
- Acorda Therapeutics
- Actavis
- Acura Pharma
- Altus formulations
- Amorsa Therapeutics
- AstraZeneca
- BioDelivery Sciences International Inc
- Cara Therapeutics
- Catalent
- Charleston
- Collegium Pharma
- Convergence
- Daiichi
- Daewoong
- Depomed
- Durect
- Egalet
- Eli Lilly
- Elite Pharma
- Endo
- Flamel Technologies
Tables:
- Table-1: US Pain Market Size
- Table-2: Classification Based on Intensity of Pain
- Table-3: Marketed Fentanyl Dosage Forms (US): Transdermal Patches, Buccal And Sublingual Tablets And Films For Pain Relief
- Table-4: Commonly Used Opioids For Pain Management
- Table-5: Marketed Drugs for Neuropathic Pain
- Table-6: Drug Enforcement Authority (DEA) Controlled Substances Schedule Criteria
- Table-7: Summary of Controlled Substances Act requirements
- Table-8: Common Non-Opioids – Acetaminophen and NSAIDs
- Table-9: Benefits of Sublingual Microtablets vs. IV morphine Patient Controlled Analgesia

Charts:
- Chart-1: Classification of Pain
- Chart-2: Pain Relief Ladder -WHO
- Chart-3: Neuropathic Pain market size and projection through 2020
- Chart-4: Global Healthcare Market Expenditure through 2018: Therapy Class
- Chart-5: Global NME (2008-12) Availability in 2013
- Chart-6: Death Rates

Ordering:
Order Online - http://www.researchandmarkets.com/reports/3068906/

Order by Fax - using the form below

Order by Post - print the order form below and send to

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.
Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to 646-607-1907 (from USA) or +353-1-481-1716 (from Rest of World). If you have any questions please visit http://www.researchandmarkets.com/contact/

Order Information
Please verify that the product information is correct and select the format(s) you require.

- **Product Name:** Moderate to Severe Pain: Novel Abuse Deterrent Formulation Technologies and Emergence of Novel Mechanism in the Management of Pain
- **Web Address:** http://www.researchandmarkets.com/reports/3068906/
- **Office Code:** SCBR9USI

**Product Formats**
Please select the product formats and quantity you require:

<table>
<thead>
<tr>
<th>Format Type</th>
<th>Quantity</th>
<th>Price</th>
</tr>
</thead>
<tbody>
<tr>
<td>Electronic (PDF) - Single User</td>
<td>✔️</td>
<td>USD 3000</td>
</tr>
<tr>
<td>Hard Copy</td>
<td>✔️</td>
<td>USD 4500 + USD 58 Shipping/Handling</td>
</tr>
<tr>
<td>Electronic (PDF) - Site License</td>
<td>✔️</td>
<td>USD 6000</td>
</tr>
<tr>
<td>Electronic (PDF) - Enterprisewide</td>
<td>✔️</td>
<td>USD 9000</td>
</tr>
<tr>
<td>CD-ROM</td>
<td>✔️</td>
<td>USD 4500 + USD 58 Shipping/Handling</td>
</tr>
</tbody>
</table>

* Shipping/Handling is only charged once per order.

**Contact Information**
Please enter all the information below in **BLOCK CAPITALS**

<table>
<thead>
<tr>
<th>Title</th>
<th>Mr</th>
<th>Mrs</th>
<th>Dr</th>
<th>Miss</th>
<th>Ms</th>
<th>Prof</th>
</tr>
</thead>
<tbody>
<tr>
<td>First Name</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Last Name</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Email Address*</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Job Title</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Organisation</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Address</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>City</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Postal / Zip Code</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Country</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Phone Number</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fax Number</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Payment Information

Please indicate the payment method you would like to use by selecting the appropriate box.

☐ Pay by credit card: You will receive an email with a link to a secure webpage to enter your credit card details.

☐ Pay by check: Please post the check, accompanied by this form, to:
Research and Markets,
Guinness Center,
Taylors Lane,
Dublin 8,
Ireland.

☐ Pay by wire transfer: Please transfer funds to:
Account number 833 130 83
Sort code 98-53-30
Swift code ULSBIE2D
IBAN number IE78ULSB98533083313083
Bank Address Ulster Bank,
27-35 Main Street,
Blackrock,
Co. Dublin,
Ireland.

If you have a Marketing Code please enter it below:
Marketing Code: 

Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp

Please fax this form to:
(646) 607-1907 or (646) 964-6609 - From USA
+353-1-481-1716 or +353-1-653-1571 - From Rest of World